Biotech

All Articles

Merck ceases phase 3 TIGIT trial in bronchi cancer for impossibility

.Merck &amp Co.'s TIGIT course has actually suffered another misfortune. Months after shuttering a p...

After a difficult year, Exscientia folds up in to Recursion

.After a year described by pipeline hairstyles, the shift of its own CEO and also discharges, Exscie...

Cullinan, after $25M package, hands back bispecific to Port

.Cullinan Therapy was actually blown away enough along with Harbour BioMed's bispecific immune syste...

A closer take a look at Strong Biotech's Tough 15

.In this week's episode of "The Leading Line," our team are actually diving right into Brutal Biotec...

Lilly experiences stage 2 failure of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's event celebrating the commendation of Alzheim...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our summary of significant leadership hirings, firings an...

Lykos will certainly inquire FDA to rethink its decision following turndown of MDMA treatment for post-traumatic stress disorder

.Adhering to a poor revealing for Lykos Therapies' MDMA candidate for post-traumatic stress disorder...

AN 2 one-halfs roll call, quits period 3 trial after data dissatisfy

.AN2 Therapeutics is actually reconsidering its own organization in reaction to uninspired midphase ...

Merck pays for $700M for bispecific, snooping autoimmune position as well as opportunity to test Amgen in cancer

.Merck &amp Co. is spending $700 thousand upfront to test Amgen in a blood cancer market. The bargai...

Gilead spends J&ampJ $320M to go out licensing offer for seladelpar

.With Gilead Sciences almost an FDA selection for its own liver ailment drug seladelpar, the busines...